Home Health

The White House Pulled Heidi Overton, Its Pick to Lead the FDA, the Day Before a Senate Committee Vote

The White House withdrew Heidi Overton's nomination to run the FDA on Tuesday night, a day before the Senate health committee was due to vote on her, and under the Vacancies Act that withdrawal hands the agency's acting…

Heidi Overton, nominee for FDA commissioner, walking through a Senate office building hallway holding a folder, with aides behind her

The White House withdrew Heidi Overton’s nomination to run the FDA on Tuesday night, a day before the Senate health committee was due to vote on her, and under the Vacancies Act that withdrawal hands the agency’s acting chief a fresh 210 days, which runs to June 15, 2027, rather than the December cutoff a seven-month limit would suggest.

  • The White House confirmed the withdrawal to The Hill on Tuesday evening. Overton, deputy director of the Domestic Policy Council, faced a Wednesday committee vote with Republicans holding 12 seats to the Democrats’ 11, so one Republican defection was enough to sink her.
  • Sen. Bill Cassidy, the Louisiana Republican who chairs the committee, wrote on X that she would have cleared it and that the holdup was anti-abortion senators wanting assurances on “life issues.”
  • No successor has been named. Kyle Diamantas, an attorney and friend of Donald Trump Jr., has been acting commissioner since Marty Makary resigned on May 12.
  • The agency has lost about 20 percent of its employees since Trump took office, AP reported.

Start with the clock the coverage gave you. AP wrote that acting officials are limited to about seven months. That is the Vacancies Act default: 210 days from the day the job opens. Makary resigned May 12. Count 210 days from there and you land on Dec. 8, exactly three weeks after the withdrawal. If that were the whole statute, the White House would be staring at a deadline just before Christmas.

It is not the whole statute. Section 3346 suspends the default while a nomination is pending in the Senate. Then it adds the line that matters. If the first nomination is “withdrawn, or returned to the President by the Senate,” the acting official “may continue to serve as the acting officer for no more than 210 days after the date of such rejection, withdrawal, or return.”

Do the arithmetic yourself. Tuesday, Nov. 17, plus 13 days is Nov. 30. December, January, February, March, April and May add 31, 31, 28, 31, 30 and 31, which brings the count to 195. Fifteen more days in June make 210. The date is June 15, 2027.

Two limits on that reading. It is the statute’s plain text, not a court’s, and a formal withdrawal message dated after Tuesday moves the date by the same number of days. Whether Diamantas was eligible to take the job under section 3345 in the first place is a separate fight this piece does not try to settle.

The clock can also be reset again. If the president sends a second nominee, subsection (b)(2) lets the acting chief serve until that person is confirmed, or for 210 days after the second nomination fails. Read together, the statute lets a White House that cannot get a commissioner through the Senate keep an acting one through next summer and past it.

C-SPAN, Sept. 24: Overton at her Senate health committee confirmation hearing, in the clip C-SPAN titled “affirms safety of vaccines.”

Now the why, because two accounts are on the table and they cannot both be right.

The White House’s version is that she lacked the votes. Cassidy’s is that she had them. He wrote that he had “productive conversations” with committee members and that “the Administration withdrew Dr. Overton rather than make such commitments.” The committee arithmetic explains why the argument exists at all: with a 12 to 11 split, a single Republican who wanted a promise on abortion was enough to stall her, and Cassidy says the promise was the price.

Here is the part that does not fit a vaccine story. Cassidy had called her support for Trump’s plan to break up combination vaccines, the measles, mumps and rubella shot among them, “almost disqualifying”, and pressed her on her independence at a Sept. 24 hearing. The Hill reported that she had stood beside Trump when he announced an order to reduce and separate the childhood vaccine schedule, called it “historic,” and declined at her hearing to say whether she would stand up to the president or to Health Secretary Robert F. Kennedy Jr. By Tuesday night Cassidy was saying her conversations with him convinced him she would “follow the science.” The coverage does not say what moved him.

We think the sequence tells you what the White House valued. The FDA is reviewing the abortion pill mifepristone at Trump’s request, a review that could bring back in-person prescribing, with a report promised by March. A commissioner confirmed on the strength of commitments about that review would have been bound by them to the senators who extracted them. An acting commissioner has made no commitments to the committee. We cannot show that was the calculation, and nobody in the administration has said so. But when the committee chair says the nominee could have been confirmed and the administration chose to withdraw her instead of making a promise, the plain reading is that it preferred the open question to the confirmed answer.

That is a bad trade for the agency. The same Tuesday, the United States lost its measles elimination status, and Kennedy said he would work to regain it. The FDA licenses the measles vaccine. It is now headed into winter with an acting chief, a fifth of its workforce gone, and a nomination fight that never produced a straight answer on whether its nominee would stand up to the president on vaccines.


What changes in January is who holds the Senate. AP reported that Republicans were racing to confirm Trump’s nominees before Democrats take over. Cassidy put it flatly in his post: “with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats.”

That leaves the White House a choice the statute makes easy. It can nominate someone a Democratic-led committee would accept, or it can leave Diamantas in place and keep the seat warm until the clock runs out in June. One report, from Axios as carried by Investing.com, says the administration is weighing Sen. Roger Marshall of Kansas. That is unconfirmed, and The Hill says it was not immediately clear whom the White House would pick.

So the question for the next six months is not whether the FDA will have a confirmed commissioner by Christmas. It almost certainly will not. The question is who the White House wants deciding mifepristone, vaccine policy and a depleted staff, and the Vacancies Act lets it answer without asking the Senate. Mark three dates: March for the mifepristone report, January for the new Senate, and June 15 for the clock.